Results 161 to 170 of about 10,477 (203)

JAK Inhibitors in Psoriatic–Atopic Dermatitis Overlap: A Four‑Case Series

JEADV Clinical Practice, Volume 5, Issue 3, Page 951-955, September 2026.
ABSTRACT Overlap between psoriasis and atopic dermatitis (AD) poses diagnostic and therapeutic challenges; monoclonal antibodies targeting a single axis may improve one component while worsening the other [1]. Janus kinase (JAK) inhibitors act pleiotropically and may provide simultaneous control of psoriatic and eczematous inflammation [2].
Eleonora Bongiovanni, Francois Rosset, Isotta Giunipero di Corteranzo, Lorenzo Bellando, Rebecca Senetta, Simone Ribero, Pietro Quaglino   +6 more
wiley   +1 more source

Cochlear Implantation in Autoimmune Inner‐Ear Disease: Outcome and Patient‐Reported Benefit

The Laryngoscope, Volume 136, Issue 9, Page 3980-3989, September 2026.
This study demonstrates that patients with secondary autoimmune inner‐ear disease (AIED) achieve significant improvements in speech perception and quality of life following cochlear implantation. Although AIED patients may show slightly lower performance in noisy environments compared to controls, their subjective hearing benefit converges with matched
Merete Hartmann, David Oestreicher, Marc Albert Hüser, Dirk Beutner, Christian Wrobel   +4 more
wiley   +1 more source

Autoimmunity: Molecular Mechanisms, Biomarkers, and Therapeutic Opportunities

MedComm, Volume 7, Issue 9, September 2026.
Major types of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming involved in autoimmune diseases. The roles of immunometabolism, epigenetics, posttranscriptional regulation, and functional reprogramming in autoimmune diseases have been a major research focus in recent years.
Jialong Kuang, Yin Zhu, Fang Xu, Yongjing Liu, Yuan Li, Ling Yuan, Liqin Wei, Bo Huang, Yan Chen, Pei Huang, Zuochen Du   +10 more
wiley   +1 more source

Efficacy, safety, and patient-reported outcomes of combination etanercept andsulfasalazine versus etanercept alone in patients with rheumatoid arthritis: adouble-blind randomized two-year study.

, 2009
OBJECTIVE: To determine the efficacy and safety of etanercept and etanercept plus sulfasalazine versus sulfasalazine in patients with rheumatoid arthritis (RA) despite sulfasalazine therapy.
KVIEN TK, FATENEJAD S., WAJDULA J, COMBE B, KHANDKER R, GAUBITZ M, FIOCCO, UGO, SINGH A, PAVELKA K, SAMBROOK PN, GEUSENS PP, CODREANU C, SMOLEN JS   +12 more
core  

Safety and Efficacy of Vedolizumab for the Patients With Gastrointestinal Acute Graft‐Versus‐Host Disease Refractory to Steroid Treatment After Allogeneic Hematopoietic Stem Cell Transplantation: A Real‐World, Retrospective Multicenter Study (VAST Study)

MedComm, Volume 7, Issue 9, September 2026.
This multicenter, real‐world study with a large sample size (i.e., vedolizumab for aGVHD refractory to steroid treatment, VAST study) was designed to identify the safety and efficacy of vedolizumab treatment in patients with steroid‐refractory gastrointestinal acute graft‐versus‐host disease (SR‐GI‐aGVHD). The overall response rates (ORR) on day 28 and
Leqing Cao, Yi Xia, Song Xue, Jianping Zhang, Jiameng Li, Yuewen Wang, Qi Wen, Ze Tian, Jun Kong, Daoxing Deng, Xiaohui Zhang, Yang Cao, Na Xu, Xiaodong Mo   +13 more
wiley   +1 more source

Cancer Neuroscience: From Local Neuro–Immune Microenvironments to Systemic Brain–Body Circuitry

MedComm, Volume 7, Issue 9, September 2026.
This review outlines the cancer neuroscience paradigm, spanning systemic brain–body circuitry and local neuro–immune–tumor microenvironments. We discuss how tumors promote axonogenesis and pseudo‐synapse formation, and how sensory neuropeptides, such as CGRP, contribute to CD8+ T‐cell exhaustion.
Mingxuan Xie, Yu Zhao, Xinruo Xing, Yuqiang Liu, Jungang Zhao, Maojin Yao, Jun Tang, Jianzhu Zhao   +7 more
wiley   +1 more source

Infection risk in rheumatoid arthritis patients treated with biologic and targeted therapies

Rheumatology &Autoimmunity, Volume 6, Issue 3, Page 149-159, September 2026.
In this context, infections associated with each biologic and targeted drug are summarized to inform the stratification of RA patients, including the characteristics of the susceptible patients and their concomitant therapy. We aim to provide a benefit‐risk analysis for clinical decision, and vital indications for the prevention of highly correlated ...
Lujing Wang, Jieshi Lin, Jie Qian
wiley   +1 more source

Anemia of Inflammation in Solid Tumor Patients and Practical Education for Oncologists and Nurses

Thoracic Cancer, Volume 17, Issue 17, September 2026.
Tumor‐ and immune‐derived cytokines including IL‐6, IL‐1β, TNF‐α, TGF‐β, IL‐10, and IFN‐γ drive anemia of inflammation: IL‐6/TNF‐α upregulate hepatic hepcidin to block iron export, while other cytokines suppress erythropoiesis and shorten red cell survival.
Xiaoyan Si, Xiaomin Wei, Xiaoyan Liu, Mei Li, Mengzhao Wang, Li Zhang   +5 more
wiley   +1 more source

International consensus on dose reduction of biologics for patients with psoriasis: The DR. Delphi study

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 9, Page 1449-1459, September 2026.
Dermatologists worldwide reached consensus on criteria for dose reduction (DR) of biologics for psoriasis resulting in a DR algorithm for adalimumab, etanercept and ustekinumab. DR of IL‐17 and IL‐23 inhibitors was deemed feasible as well. This first international consensus provides essential information for uptake of biologic DR for psoriasis globally.
C. A. M. van Riel, W.‐H. Boehncke, J. L. W. Lambert, P. I. Spuls, L. S. van der Schoot, I. van Ee, E. M. G. J. de Jong, J. M. P. A. van den Reek, on behalf of the eDelphi consortium, M. Elkalioby, L. Fianen, L. Linhares Leite, C. Boesjes, S. Mahil, M. Franco, F. Valenzuela, C. Chaiyabutr, M. A. Lorna, F. Frez, O. Zargari, T. Hillary, H. Oon, L. Skov, M. Gupta, E. Sotiriou, N. Nguyen Loft, R. Ceovic, K. M. G. Klaassen, J. Wikström, C. Zachariae, P. Asawanonda, R. Vender, A. Carvalho, J. Song, C. Lan, J.‐T. Maul, D. Jullien, B. Hidalgo‐Matlock, A. Duvetorp, M. Gkini, D. Ioannidis, W. Veldkamp, J. Hugo, J. Barboza, A. Carugno, A. Londoño‐García, L. Schneller‐Pavelescu Apetrei, M. Ferran, F. Lafuente Urrez, N. Merino, M. Llamas Velasco, L. Puig, M. Bourcier, M. Perez Ferriols, T. Leonidze, D. Armijo, A. Eylenbosch, M. B. A. van Doorn, P. P. M. van Lumig, P. Ghislain, A. Nast, S. Lanssens, E. Sonkoly, D. J. Hijnen, E. M. Baerveldt, P. Gisondi, M. Tjioe, I. Haeck, K. Agerberg, Y. Okubo   +69 more
wiley   +1 more source

Systemic Therapy for Paediatric Stevens–Johnson Syndrome and Toxic Epidermal Necrolysis: A Systematic Review of Current Evidence and Limitations

Journal of Paediatrics and Child Health, Volume 62, Issue 9, Page 1570-1577, September 2026.
ABSTRACT Aim The role of systemic therapy in paediatric Stevens–Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) remains undefined. Management is primarily guided by observational data and variable practice patterns. This systematic review aims to integrate recent evidence and evaluate clinical outcomes associated with systemic therapies in ...
Samantha Ting, Kangjie Reuel Chua, Li‐Chuen Wong, Gloria Fong   +3 more
wiley   +1 more source